Major scientific leaps, such as CRISPR (from bacterial defense) or cancer immunotherapy (from basic T-cell biology), rarely come from direct attempts to solve the problems they ultimately fix. They are "orthogonal" discoveries born from fundamental research into seemingly unrelated questions.

Major advancements in biotech instrumentation are not just software or AI achievements. They are the result of a deeply multidisciplinary effort over many years, requiring innovations and integration across optics, fluidics, chemistry, hardware, and biology to create powerful new tools.

Derek Small argues the breakthrough in neuroscience mirrors oncology's shift from blunt instruments to targeted therapies. By focusing on underlying pathology like synaptic dysfunction and neuroinflammation, rather than just symptoms, developers can achieve biomarker-based approvals and more effective treatments.

CZI set an audacious goal to cure all disease. When scientists deemed it impossible, CZI's follow-up question, "Why not?" revealed the true bottleneck wasn't funding individual projects, but a systemic lack of shared tools, which then became their core focus.

The first iPSC therapies focused on CNS and eye diseases not because they were the biggest markets, but because their differentiation protocols were discovered first—sometimes by accident, like leaving cells in an incubator over Christmas break. This shows how scientific serendipity, not strategy, can shape a field's initial direction.

Treating the brain as a computational device allows for an engineering-driven approach to solving neurological issues. This yields more predictable results and faster progress compared to the "random walk" of small molecule drug discovery, which often ends in failure after years of research.

Instead of funding small, incremental research grants, CZI's philanthropic strategy focuses on developing expensive, long-term tools like AI models and imaging platforms. This provides leverage to the entire scientific community, accelerating the pace of the whole field.

Patrick Collison believes we can finally cure complex diseases because biology now has a complete 'Turing loop': advanced sequencing to 'read' biological data, neural networks to 'think' about it, and CRISPR to 'write' changes by perturbing cells. This combination provides the necessary toolset for breakthroughs.

The recent increase in neurology-focused investment and M&A isn't just a cyclical market trend. It's driven by fundamental scientific progress, including validated biological targets and improved biomarker strategies. These advances are de-risking a historically challenging field, making investors more confident in long-term commitments beyond typical market cycles.